Skip to main content

Site notifications

Notice for trastuzumab deruxtecan (AstraZeneca Pty Ltd)

Active ingredients
trastuzumab deruxtecan
Date of review outcome
Lapse date
Priority review
ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with hormone receptor-positive breast cancer should additionally have received or be ineligible for endocrine therapy.
Therapeutic area

Help us improve the Therapeutic Goods Administration site